MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
MAIA Biotechnology, Inc. (MAIA)
Company Research
Source: GlobeNewswire
High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for ateganosine in NSCLC advances concurrent Phase 2 expansion and Phase 3 trials along strategic regulatory pathways Strong momentum toward goal of early commercial approval Potential breakthrough therapeutic for estimated $50+ billion global immunotherapy market; first and only telomere-targeting anticancer agent in clinical development anywhere CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a corporate update on 2025 achievements and highlighted key targeted milestones and growth catalysts for 2026. “MAIA’s strong clinical execution in 2025 delivered exceptional efficacy data for ateganosine sequenced with a c
Show less
Read more
Impact Snapshot
Event Time:
MAIA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAIA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAIA alerts
High impacting MAIA Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
MAIA
News
- Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) [Yahoo! Finance]Yahoo! Finance
- MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings [Yahoo! Finance]Yahoo! Finance
- MAIA Biotechnology Board Members Continue to Participate in Private Placement FinancingsGlobeNewswire
- MAIA Biotechnology Announces $1.51 Million Private PlacementGlobeNewswire
- MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates [Yahoo! Finance]Yahoo! Finance
MAIA
Sec Filings
- 1/20/26 - Form 8-K
- 1/13/26 - Form 8-K
- 1/12/26 - Form 4
- MAIA's page on the SEC website